A new lawsuit filed in Massachusetts this week joins the growing Depo‑Provera MDL. The plaintiff alleges that years of Depo‑Provera injections led to a large intracranial meningioma in 2022. She received treatment from 2016 to 2022 and now has ongoing neurological issues and psychological injuries.
This case highlights how the Depo‑Provera mass tort is expanding beyond Florida. The MDL, centralized in the Northern District of Florida under Judge M. Casey Rodgers, now includes at least 348 federal cases tied to brain tumor claims.
Experts say this Massachusetts filing strengthens the geographic reach and credibility of the MDL. It further challenges Pfizer’s defense that only certain regions have impacted users.
The next major event is the preemption oral argument, scheduled for September 29, 2025. Judge Rodgers will hear Pfizer’s argument that the FDA’s rejection of a meningioma warning bars state-level failure-to-warn claims. The outcome could dismiss hundreds of cases before trial.
Between now and September, plaintiffs will continue depositing experts and pursuing discovery. The new Massachusetts case intensifies pressure on Pfizer as more women step forward with similar claims.
